← Back to Clinical Trials
Recruiting NCT02325674
MEASuRE: Metreleptin Effectiveness And Safety Registry
Trial Parameters
Condition Generalised Lipodystrophy
Sponsor Amryt Pharma
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2016-10-11
Completion 2031-10-31
All Conditions
Interventions
Metreleptin
Brief Summary
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Eligibility Criteria
Inclusion Criteria: * Patients treated with metreleptin through commercial supply at the time or before enrolment into registry * Patients who provide a written consent * Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply Exclusion Criteria: • Patients currently treated with an investigational agent as part of a clinical trial